Immunobiology of mesenchymal stem cells

Cell Death and Differentiation

Volumn 21, Issue 2, 2014, Pages 216-225

  Ma, S ^a   Xie, N ^a   Li, W ^a   Yuan, B ^b   Shi, Y ^a,c   Wang, Y ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c CHILD HEALTH INSTITUTE OF NEW JERSEY   (United States)

Author keywords

3 dioxygenase; engraftment; immunoregulation; indoleamine 2; inflammatory diseases; mesenchymal stem cells; nitric oxide

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN; FIBROBLAST GROWTH FACTOR; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH FACTOR; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN C; STEM CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN;

CELL DIFFERENTIATION; CELL FUNCTION; CELL ISOLATION; CELL LINEAGE; DISEASE COURSE; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOBIOLOGY; INFLAMMATION; INFLAMMATORY DISEASE; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; REVIEW; TISSUE INJURY; ANIMAL; CYTOLOGY; HUMAN; IMMUNOLOGY; MESENCHYMAL STROMA CELL;

ANIMALS; HUMANS; INFLAMMATION; MESENCHYMAL STROMAL CELLS;

EID: 84892433295     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.158     Document Type: Review

References (148)

1. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nature Rev Immunol 2008; 8: 726-762.
2. Portmann-Lanz CB, Schoeberlein A, Huber A, Sager R, Malek A, Holzgreve W et al. Placental mesenchymal stem cells as potential autologous graft for pre-and perinatal neuroregeneration. Am J Obstet and Gynecol 2006; 194: 664-673. (Pubitemid 43333137)
3. Musina RA, Belyavski AV, Tarusova OV, Solovyova EV, Sukhikh GT. Endometrial mesenchymal stem cells isolated from the menstrual blood. Bull Exp Biol Med 2008; 145: 539-543.
4. Steigman SA, Fauza DO. Isolation of mesenchymal stem cells from amniotic fluid and placenta. Curr Protoc Stem Cell Biol 2007; 1: 1E.2.1-1E.2.12.
5. Tirino V, Paino F, d'Aquino R, Desiderio V, De Rosa A, Papaccio G. Methods for the identification, characterization and banking of human DPSCs: current strategies and perspectives. Stem Cell Rev 2011; 7: 608-615.
6. Friedenstein AJ, Chailakhyan RK, Latsinik NV, Panasyuk AF, Keiliss-Borok IV. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974; 17: 331-340.
7. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147. (Pubitemid 29282067)
8. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003; 174: 101-109. (Pubitemid 36819010)
9. Mackay AM, Beck SC, Murphy JM, Barry FP, Chichester CO, Pittenger MF. Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 1998; 4: 415-428. (Pubitemid 28553528)
10. Tropel P, Platet N, Platel JC, Noël D, Albrieux M, Benabid AL et al. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006; 24: 2868-2876. (Pubitemid 46053023)
11. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528-1530. (Pubitemid 28217075)
12. Corselli M, Chen CW, Crisan M, Lazzari L, Péault B. Perivascular ancestors of adult multipotent stem cells. Arterioscler Thromb Vasc Biol 2010; 30: 1104-1109.
13. Crisan M, Yap S, Casteilla L, Chen CW, Corselli M, Park TS et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008; 3: 301-313.
14. Hirschi KK, D'Amore PA. Pericytes in the microvasculature. Cardiovasc Res. 1996; 32: 687-698. (Pubitemid 26332308)
15. Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Boström K et al. Multilineage potential of cells from the artery wall. Circulation 2003; 108: 2505-2510. (Pubitemid 37444413)
16. Hoshino A, Chiba H, Nagai K, Ishii G, Ochiai A. Human vascular adventitial fibroblasts contain mesenchymal stem/progenitor cells. Biochem Biophys Res Commun 2008; 368: 305-310.
17. Chidgey AP, Layton D, Trounson A, Boyd RL. Tolerance strategies for stem-cell-based therapies. Nature 2008; 453: 330-337. (Pubitemid 351693139)
18. Shi Y, Hu G, Su J, Li W, Chen Q, Shou P et al. Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res 2010; 20: 510-518.
19. Eming SA, Krieg T, Davidson JM. Inflammation in wound repair: molecular and cellular mechanisms. J Invest Dermatol 2007; 127: 514-525.
20. Luster AD, Alon R, von Andrian UH. Immune cell migration in inflammation: present and future therapeutic targets. Nat Immunol 2005; 6: 1182-1190. (Pubitemid 43045626)
21. Krysko DV, Denecker G, Festjens N, Gabriels S, Parthoens E, D'Herde K et al. Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells. Cell Death Differ 2006; 13: 2011-2022. (Pubitemid 44742684)
22. Shi Y, Su J, Roberts AI, Shou P, Rabson AB, Ren G. How mesenchymal stem cells interact with tissue immune responses. Trends Immunol 2012; 33: 136-143.
23. Ma XL, Liu KD, Li FC, Jiang XM, Jiang L, Li HL. Human mesenchymal stem cells increases expression of a-tubulin and angiopoietin 1 and 2 in focal cerebral ischemia and reperfusion. Curr Neurovasc Res 2013; 10: 103-111.
24. Aguilar S, Scotton CJ, McNulty K, Nye E, Stamp G, Laurent G et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009; 4: e8013.
25. Hung SP, Yang MH, Tseng KF, Lee OK. Hypoxia-induced secretion of TGF-beta 1 in mesenchymal stem cell promotes breast cancer cell progression. Cell Transplant 2012; 22: 1869-1882.
26. Giacca M, Zacchigna S. VEGF gene therapy: therapeutic angiogenesis in the clinic and beyond. Gene Ther 2012; 19: 622-629.
27. Lee JW, Fang X, Krasnodembskaya A, Howard JP, Matthay MA. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells 2011; 29: 913-919.
28. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One 2008; 3: e1886.
29. Gnecchi M, He H, Liang OD, Melo LG, Morello F, Mu H et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005; 11: 367-368. (Pubitemid 40562318)
30. Timmers L, Lim SK, Hoefer IE, Arslan F, Lai RC, van Oorschot AA et al. Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Res 2011; 6: 206-214.
31. Van Overstraeten-Schlögel N, Beguin Y, Gothot A. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells. Eur J Haematol 2006; 76: 488-493.
32. Nasef A, Mazurier C, Bouchet S, François S, Chapel A, Thierry D et al. Leukemia inhibitory factor: Role in human mesenchymal stem cells mediated immunosuppression. Cell Immunol 2008; 253: 16-22.
33. Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q et al. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia 2008; 56: 686-698.
34. Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci 2012; 15: 862-870.
35. Cao W, Yang Y, Wang Z, Liu A, Fang L, Wu F et al. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity 2011; 35: 273-284.
36. Pfeifer R, Lichte P, Schreiber H, Sellei RM, Dienstknecht T, Sadeghi C et al. Models of hemorrhagic shock: differences in the physiological and inflammatory response. Cytokine 2013; 61: 585-590.
37. Liu C, Tao Q, Sun M, Wu JZ, Yang W, Jian P et al. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in hepatic fibrosis in rats. Lab Invest 2010; 90: 1805-1816.
38. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126. (Pubitemid 40656164)
39. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C et al. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by tnFalpha. Cell Stem Cell 2012; 11: 812-824.
40. Németh K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, Doi K et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 2009; 15: 42-49.
41. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24: 74-85.
42. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 2006; 107: 1484-1490. (Pubitemid 43242385)
43. Mougiakakos D, Jitschin R, Johansson CC, Okita R, Kiessling R, Le Blanc K. The impact of inflammatory licensing on heme oxygenase-1-mediated induction of regulatory T cells by human mesenchymal stem cells. Blood 2011; 117: 4826-4835.
44. Svobodova E, Krulova M, Zajicova A, Pokorna K, Prochazkova J, Trosan P et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012; 21: 901-910.
45. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729. (Pubitemid 36857965)
46. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006; 107: 367-372. (Pubitemid 43053565)
47. Ren G, Su J, Zhang L, Zhao X, Ling W, L'Huillie A et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009; 27: 1954-1962.
48. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI et al. Mesenchymal stem cellmediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-150. (Pubitemid 351181031)
49. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586. (Pubitemid 351626841)
50. Sun L, Akiyama K, Zhang H, Yamaza T, Hou Y, Zhao S et al. Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009; 27: 1421-1432.
51. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geissler EK et al. Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation 2006; 81: 1589-1595. (Pubitemid 43890897)
52. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B et al. Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graftversus-host disease in mice. J Immunol 2006; 176: 7761-7767. (Pubitemid 43849077)
53. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J. Allogeneic marrow stromal cells are immune rejected by MHC class I-and class II-mismatched recipient mice. Blood 2005; 106: 4057-4065. (Pubitemid 41775910)
54. Rafei M, Birman E, Forner K, Galipeau J. Allogeneic mesenchymal stem cells for treatment of experimental autoimmune encephalomyelitis. Mol Ther 2009; 17: 1799-1803.
55. Wu J, Sun Z, Sun HS, Weisel RD, Keating A, Li ZH et al. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant 2008; 16: 993-1005. (Pubitemid 351732841)
56. Crisostomo PR, Wang M, Wairiuko GM, Morrell ED, Terrell AM, Seshadri P et al. High passage number of stem cells adversely affects stem cell activation and myocardial protection. Shock 2006; 26: 575-580. (Pubitemid 44789631)
57. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W et al. Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010; 184: 2321-2328.
58. Blesson S, Thiery J, Gaudin C, Stancou R, Kolb JP, Moreau JL et al. Analysis of the mechanisms of human cytotoxic T lymphocyte response inhibition by NO. Int Immunol 2002; 14: 1169-1178. (Pubitemid 35175224)
59. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-916. (Pubitemid 32976162)
60. Staykova MA, Berven LA, Cowden WB, Willenborg DO, Crouch MF. Nitric oxide induces polarization of actin in encephalitogenic T cells and inhibits their in vitro trans-endothelial migration in a p70S6 kinase-independent manner. FASEB J 2003; 17: 1337-1339.
61. Chabannes D, Hill M, Merieau E, Rossignol J, Brion R, Soulillou JP et al. A role for heme oxygenase-1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. Blood 2007; 110: 3691-3694. (Pubitemid 350159638)
62. Sato K, Ozaki K, Oh I, Meguro A, Hatanaka K, Nagai T et al. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007; 109: 228-234. (Pubitemid 46053063)
63. Bouffi C, Bony C, Courties G, Jorgensen C, Noë l D. IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010; 5: e14247.
64. Rafei M, Campeau PM, Aguilar-Mahecha A, Buchanan M, Williams P, Birman E et al. Mesenchymal stromal cells ameliorate experimental autoimmune encephalomyelitis by inhibiting CD4 Th17 T cells in a CC chemokine ligand 2-dependent manner. J Immunol 2009; 182: 5994-6002.
65. Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A et al. Role for interferongamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells 2006; 24: 386-398. (Pubitemid 44464808)
66. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 2004; 103: 4619-4621. (Pubitemid 38745993)
67. Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004; 4: 762-774. (Pubitemid 39336293)
68. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009; 5: 54-63.
69. Oh JY, Lee RH, Yu JM, Ko JH, Lee HJ, Ko AY et al. Intravenous mesenchymal stem cells prevented rejection of allogeneic corneal transplants by aborting the early inflammatory response. Mol Ther 2012; 20: 2143-2152.
70. Roddy GW, Oh JY, Lee RH, Bartosh TJ, Ylostalo J, Coble K et al. Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TNF-alpha stimulated gene/protein 6. Stem Cells 2011; 29: 1572-1579.
71. Choi H, Lee RH, Bazhanov N, Oh JY, Prockop DJ. Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-kappaB signaling in resident macrophages. Blood 2011; 118: 330-338.
72. Nasef A, Mathieu N, Chapel A, Frick J, François S, Mazurier C et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007; 84: 231-237. (Pubitemid 47205757)
73. Gieseke F, Böhringer J, Bussolari R, Dominici M, Handgretinger R, Müller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010; 116: 3770-3779.
74. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005; 105: 1815-1822. (Pubitemid 40223708)
75. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood 2009; 113: 6576-6583.
76. Gu YZ, Xue Q, Chen YJ, Yu GH, Qing MD, Shen Y et al. Different roles of PD-L1 and FasL in immunomodulation mediated by human placenta-derived mesenchymal stem cells. Hum Immunol 2013; 74: 267-276.
77. Fiorina P, Jurewicz M, Augello A, Vergani A, Dada S, La Rosa S et al. Immunomodulatory function of bone marrow-derived mesenchymal stem cells in experimental autoimmune type 1 diabetes. J Immunol 2009; 183: 993-1004.
78. Matysiak M, Orlowski W, Fortak-Michalska M, Jurewicz A, Selmaj K. Immunoregulatory function of bone marrow mesenchymal stem cells in EAE depends on their differentiation state and secretion of PGE2. J Neuroimmunol 2011; 233: 106-111.
79. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 2008; 111: 1327-1333. (Pubitemid 351213419)
80. Beyth S, Borovsky Z, Mevorach D, Liebergall M, Gazit Z, Aslan H et al. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 2005; 105: 2214-2219. (Pubitemid 40731815)
81. Groh ME, Maitra B, Szekely E, Koç ON. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp Hematol 2005; 33: 928-934. (Pubitemid 40982660)
82. Rasmusson I, Ringdén O, Sundberg B, Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 2005; 305: 33-41. (Pubitemid 40380651)
83. Xu G, Zhang L, Ren G, Yuan Z, Zhang Y, Zhao RC et al. Immunosuppressive properties of cloned bone marrow mesenchymal stem cells. Cell Res 2007; 17: 240-248. (Pubitemid 46438724)
84. Li W, Ren G, Huang Y, Su J, Han Y, Li J et al. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19: 1505-1513.
85. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439-1441. (Pubitemid 38586721)
86. Kuo YR, Goto S, Shih HS, Wang FS, Lin CC, Wang CT et al. Mesenchymal stem cells prolong composite tissue allotransplant survival in a swine model. Transplantation 2009; 87: 1769-1777.
87. Renner P, Eggenhofer E, Rosenauer A, Popp FC, Steinmann JF, Slowik P et al. Mesenchymal stem cells require a sufficient, ongoing immune response to exert their immunosuppressive function. Transplant Proc 2009; 41: 2607-2611.
88. Chan JL, Tang KC, Patel AP, Bonilla LM, Pierobon N, Ponzio NM et al. Antigenpresenting property of mesenchymal stem cells occurs during a narrow window at low levels of interferon-gamma. Blood 2006; 107: 4817-4824. (Pubitemid 43882633)
89. Romieu-Mourez R, Stock-Martineau S, Boivin MN, Bramson JL, Galipeau J. Mesenchymal stromal cells cross-present soluble exogenous antigens as part of their antigen-presenting cell properties. Blood 2009; 114: 2632-2638.
90. Sarkar D, Vemula PK, Zhao W, Gupta A, Karnik R, Karp JM. Engineered mesenchymal stem cells with self-assembled vesicles for systemic cell targeting. Biomaterials 2010; 31: 5266-5274.
91. Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001; 7: 430-436. (Pubitemid 32298545)
92. Wang CH, Cherng WJ, Yang NI, Kuo LT, Hsu CM, Yeh HI et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2008; 28: 54-60.
93. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E et al. Adiposederived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 2009; 27: 2624-2635.
94. Yabana T, Arimura Y, Tanaka H, Goto A, Hosokawa M, Nagaishi K et al. Enhancing epithelial engraftment of rat mesenchymal stem cells restores epithelial barrier integrity. J Pathol 2009; 218: 350-359.
95. Sutton EJ, Boddington SE, Nedopil AJ, Henning TD, Demos SG, Baehner R et al. An optical imaging method to monitor stem cell migration in a model of immune-mediated arthritis. Opt Express 2009; 17: 24403-24413.
96. Chen M, Su W, Lin X, Guo Z, Wang J, Zhang Q et al. Adoptive transfer of human gingivaderived mesenchymal stem cells ameliorates collagen-induced arthritis via suppression of Th1 and Th17 Cells and enhancement of regulatory T cell differentiation. Arthritis Rheum 2013; 65: 1181-1193.
97. Shin L, Peterson DA. Impaired therapeutic capacity of autologous stem cells in a model of type 2 diabetes. Stem Cells Transl Med 2012; 1: 125-135.
98. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009; 4: 206-216.
99. Rombouts WJ, Ploemacher RE. Primary murine MSC show highly efficient homing to the bone marrow but lose homing ability following culture. Leukemia 2003; 17: 160-170. (Pubitemid 36175902)
100. Hung SC, Pochampally RR, Hsu SC, Sanchez C, Chen SC, Spees J et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2007; 2: e416.
101. Shi M, Li J, Liao L, Chen B, Li B, Chen L et al. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematologica 2007; 92: 897-904. (Pubitemid 350144236)
102. Sordi V, Malosio ML, Marchesi F, Mercalli A, Melzi R, Giordano T et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005; 106: 419-427. (Pubitemid 40981232)
103. Plotnikov EY, Pulkova NV, Pevzner IB, Zorova LD, Silachev DN, Morosanova MA et al. Inflammatory pre-conditioning of mesenchymal multipotent stromal cells improves their immunomodulatory potency in acute pyelonephritis in rats. Cytotherapy 2013; 15: 679-689.
104. Zonta S, De Martino M, Bedino G, Piotti G, Rampino T, Gregorini M et al. Which is the most suitable and effective route of administration for mesenchymal stem cell-based immunomodulation therapy in experimental kidney transplantation: endovenous or arterial Transplant Proc 2010; 42: 1336-1340.
105. Freyman T, Polin G, Osman H, Crary J, Lu M, Cheng L et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 2006; 27: 1114-1122.
106. Lu D, Li Y, Wang L, Chen J, Mahmood A, Chopp M. Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury. J Neurotrauma 2001; 18: 813-819. (Pubitemid 32769777)
107. Walczak P, Zhang J, Gilad AA, Kedziorek DA, Ruiz-Cabello J, Young RG et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.
108. Muschler GF, Nakamoto C, Griffith LG. Engineering principles of clinical cell-based tissue engineering. J Bone Joint Surg Am 2004; 86-A: 1541-1558. (Pubitemid 38886548)
109. Chang YK, Chen MH, Chiang YH, Chen YF, Ma WH, Tseng CY et al. Mesenchymal stem cell transplantation ameliorates motor function deterioration of spinocerebellar ataxia by rescuing cerebellar Purkinje cells. J Biomed Sci 2011; 18: 54.
110. Castelo-Branco MT, Soares ID, Lopes DV, Buongusto F, Martinusso CA, do Rosario A Jr et al. Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One 2012; 7: e33360.
111. Chan J, Waddington SN, O'Donoghue K, Kurata H, Guillot PV, Gotherstrom C et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells 2007; 25: 875-884. (Pubitemid 46572584)
112. Duijvestein M, Wildenberg ME, Welling MM, Hennink S, Molendijk I, van Zuylen VL et al. Pretreatment with interferon-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29: 1549-1558.
113. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001; 32: 1005-1011. (Pubitemid 32285175)
114. Kim SW, Zhang HZ, Guo L, Kim JM, Kim MH. Amniotic mesenchymal stem cells enhance wound healing in diabetic NOD/SCID mice through high angiogenic and engraftment capabilities. PLoS One 2012; 7: e41105.
115. Khalili S, Liu Y, Kornete M, Roescher N, Kodama S, Peterson A et al. Mesenchymal stromal cells improve salivary function and reduce lymphocytic infiltrates in mice with Sjö gren's-like disease. PLoS One 2012; 7: e38615.
116. Yang M, Li Q, Sheng L, Li H, Weng R, Zan T. Bone marrow-derived mesenchymal stem cells transplantation accelerates tissue expansion by promoting skin regeneration during expansion. Ann Surg 2011; 253: 202-209.
117. Park HJ, Shin JY, Lee BR, Kim HO, Lee PH. Mesenchymal stem cells augment neurogenesis in the subventricular zone and enhance differentiation of neural precursor cells into dopaminergic neurons in the substantia nigra of a parkinsonian model. Cell Transplant 2012; 21: 1629-1640.
118. Chung R, Foster BK, Zannettino AC, Xian CJ. Potential roles of growth factor PDGF-BB in the bony repair of injured growth plate. Bone 2009; 44: 878-885.
119. Houchen CW, George RJ, Sturmoski MA, Cohn SM. FGF-2 enhances intestinal stem cell survival and its expression is induced after radiation injury. Am J Physiol 1999; 276: G249-G258. (Pubitemid 29063623)
120. Yoon BS, Moon JH, Jun EK, Kim J, Maeng I, Kim JS et al. Secretory profiles and wound healing effects of human amniotic fluid-derived mesenchymal stem cells. Stem Cells Dev 2010; 19: 887-902.
121. Hayashi Y, Tsuji S, Tsujii M, Nishida T, Ishii S, Iijima H et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J Pharmacol Exp Ther 2008; 326: 523-531.
122. Beckermann BM, Kallifatidis G, Groth A, Frommhold D, Apel A, Mattern J et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer 2008; 99: 622-631.
123. Wu Y, Chen L, Scott PG, Tredget EE. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells 2007; 25: 2648-2659. (Pubitemid 47582758)
124. Kilroy GE, Foster SJ, Wu X, Ruiz J, Sherwood S, Heifetz A et al. Cytokine profile of human adipose-derived stem cells: expression of angiogenic, hematopoietic, and pro-inflammatory factors. J Cell Physiol 2007; 212: 702-709. (Pubitemid 47271882)
125. Wakabayashi K, Nagai A, Sheikh AM, Shiota Y, Narantuya D, Watanabe T et al. Transplantation of human mesenchymal stem cells promotes functional improvement and increased expression of neurotrophic factors in a rat focal cerebral ischemia model. J Neurosci Res 2010; 88: 1017-1025.
126. Kwon DS, Gao X, Liu YB, Dulchavsky DS, Danyluk AL, Bansal M et al. Treatment with bone marrow-derived stromal cells accelerates wound healing in diabetic rats. Int Wound J 2008; 5: 453-463. (Pubitemid 351874520)
127. Hou X, Wu X, Ma J, Lv X, Jin X. Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia. Mol Biol Rep 2010; 37: 1467-1475.
128. Whone AL, Kemp K, Sun M, Wilkins A, Scolding NJ. Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Res 2012; 1431: 86-96.
129. Wang F, Yasuhara T, Shingo T, Kameda M, Tajiri N, Yuan WJ et al. Intravenous administration of mesenchymal stem cells exerts therapeutic effects on parkinsonian model of rats: focusing on neuroprotective effects of stromal cell-derived factor-1alpha. BMC Neurosci 2010; 11: 52.
130. Landry Y, Lê O, Mace KA, Restivo TE, Beauséjour CM. Secretion of SDF-1alpha by bone marrow-derived stromal cells enhances skin wound healing of C57BL/6 mice exposed to ionizing radiation. J Cell Mol Med 2010; 14: 1594-1604.
131. Li N, Lu X, Zhao X, Xiang FL, Xenocostas A, Karmazyn M et al. Endothelial nitric oxide synthase promotes bone marrow stromal cell migration to the ischemic myocardium via upregulation of stromal cell-derived factor-1alpha. Stem Cells 2009; 27: 961-970.
132. François M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 2012; 20: 187-195.
133. Lepelletier Y, Lecourt S, Renand A, Arnulf B, Vanneaux V, Fermand JP et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010; 19: 1075-1079.
134. Xue Q, Luan XY, Gu YZ, Wu HY, Zhang GB, Yu GH et al. The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 2010; 19: 27-38.
135. Rizzo R, Campioni D, Stignani M, Melchiorri L, Bagnara GP, Bonsi L et al. A functional role for soluble HLA-G antigens in immune modulation mediated by mesenchymal stromal cells. Cytotherapy 2008; 10: 364-375. (Pubitemid 351983160)
136. Wang N, Li Q, Zhang L, Lin H, Hu J, Li D et al. Mesenchymal stem cells attenuate peritoneal injury through secretion of TSG-6. PLoS One 2012; 7: e43768.
137. Djouad F, Charbonnier LM, Bouffi C, Louis-Plence P, Bony C, Apparailly F et al. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007; 25: 2025-2032. (Pubitemid 47258180)
138. Najar M, Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N et al. Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 2009; 11: 570-583.
139. Tasso R, Ilengo C, Quarto R, Cancedda R, Caspi RR, Pennesi G. Mesenchymal stem cells induce functionally active T-regulatory lymphocytes in a paracrine fashion and ameliorate experimental autoimmune uveitis. Invest Ophthalmol Vis Sci 2012; 53: 786-793.
140. Nemeth K, Keane-Myers A, Brown JM, Metcalfe DD, Gorham JD, Bundoc VG et al. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc Natl Acad Sci USA 2010; 107: 5652-5657.
141. Patel SA, Meyer JR, Greco SJ, Corcoran KE, Bryan M, Rameshwar P. Mesenchymal stem cells protect breast cancer cells through regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol 2010; 184: 5885-5894.
142. Qu X, Liu X, Cheng K, Yang R, Zhao RC. Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol 2012; 40: 761-770.
143. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, Mahon BP. Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4\+CD25(High) forkhead box P3\+ regulatory T cells. Clin Exp Immunol 2009; 156: 149-160.
144. Ylöstalo JH, Bartosh TJ, Coble K, Prockop DJ. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 2012; 30: 2283-2296.
145. Luz-Crawford P, Noël D, Fernandez X, Khoury M, Figueroa F, Carrión F et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012; 7: e45272.
146. Tipnis S, Viswanathan C, Majumdar AS. Immunosuppressive properties of human umbilical cord-derived mesenchymal stem cells: role of B7-H1 and IDO. Immunol Cell Biol 2010; 88: 795-806.
147. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, Wang L et al. A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 2008; 18: 846-857.
148. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T et al. Mesenchymal-stemcell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis. Cell Stem Cell 2012; 10: 544-555.